NAGASAWA Shun

写真a

Affiliation

Faculty of Medicine School of Medicine Department of community Pediatrics and Support Raising Next-Generation
To the head of this page.▲
 

Papers 【 display / non-display 】

  • Steroid-refractory gastrointestinal acute graft-versus-host disease treated with vedolizumab and ruxolitinib in a pediatric patient with therapy-related acute myeloid leukemia

    NAGASAWA Shun, YAMADA Ai, KINOSHITA Mariko, KAMIMURA Sachiyo, TANAKA Hiroyuki, NISHIKAWA Takuro, OKAMOTO Yasuhiro, MORITAKE Hiroshi

    Rinsho Ketsueki   64 ( 1 )   23 - 29   2023

    　More details

    Language：Japanese   Publishing type：Research paper (scientific journal)   Publisher：The Japanese Society of Hematology  

    A 12-year-old girl developed Philadelphia chromosome-positive acute myeloid leukemia due to therapy-related myelodysplastic syndrome with monosomy 7 following neuroblastoma treatment. She underwent allogenic bone marrow transplantation from a human leukocyte antigens-DR1 locus-mismatched unrelated donor. However, on day 49 post transplantation, she presented with diarrhea due to gastrointestinal acute graft-versus-host disease (aGVHD), and treatments with prednisolone, budesonide rectal foam, and human mesenchymal stem cells were ineffective. Therefore, vedolizumab was administered from day 100, which improved the symptoms from gut stage 3 to gut stage 1. Consequently, prednisolone was withdrawn without any serious adverse effects. However, the symptoms worsened to gut stage 3 again; therefore, ruxolitinib was administered to achieve complete remission. Vedolizumab exhibits gut-selective action without systemic immunosuppressive activity. Hence, vedolizumab administration before other systemic immunosuppressive agents may be recommended in patients with steroid-refractory gastrointestinal aGVHD. Thus far, only a few reports have been published regarding the administration of vedolizumab and ruxolitinib for steroid-refractory gastrointestinal aGVHD in children. Further evidence should be obtained from patients treated with vedolizumab and ruxolitinib to confirm their effectiveness for pediatric steroid-refractory gastrointestinal aGVHD.

    DOI： 10.11406/rinketsu.64.23

    PubMed

    CiNii Research

  • Successful treatment of paraspinal/spinal epidural lymphoma by early intervention and local control with proton beam therapy Reviewed

    Shun Nagasawa

    Pediatric International   64 ( 1 )   2021.1

    　More details

    Authorship：Lead author   Publishing type：Case report  

    DOI： 10.1111/ped.14970.

To the head of this page.▲